Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
RATIONALE: When irradiated lymphocytes from a donor are infused into the patient they may help the patient's immune system kill cancer cells.
PURPOSE: This pilot study is looking at the side effects and how well irradiated donor lymphocyte infusion works in treating patients with relapsed or refractory hematologic cancer or solid tumor.
Full description
OBJECTIVES:
OUTLINE: This is a pilot, open-label, controlled study.
Patients undergo irradiated allogeneic donor lymphocyte infusion over 1 hour on day 1. Treatment repeats every 8-16 weeks for up to 6 infusions in the absence of disease progression or unacceptable toxicity.
Blood samples are collected periodically and analyzed for lymphocytotoxicity directed towards patients' cells (normal and malignant cells) and for disease or antigen-specific cells. Samples are also analyzed for survival of donor lymphocytes by chimerism studies.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
Enrollment
Sex
Volunteers
Inclusion and exclusion criteria
DISEASE CHARACTERISTICS:
Histologically confirmed diagnosis of 1 of the following:
Hematologic cancer, including any of the following:
Chronic lymphocytic leukemia or small lymphocytic lymphoma meeting any of the following criteria:
B- or T-cell prolymphocytic leukemia meeting any of the following criteria:
Lymphoplasmacytic lymphoma, marginal zone lymphoma, mucosa-associated lymphoid tissue lymphoma, or follicular lymphoma meeting any of the following criteria:
Multiple myeloma meeting any of the following criteria:
Mantle cell lymphoma that has relapsed after prior combination chemotherapy or anti-CD20 monoclonal antibody OR not a candidate to receive such therapy
Diffuse large B-cell lymphoma meeting any of the following criteria:
Burkitt's lymphoma
Lymphomatoid granulomatosis or mature T-cell or NK-cell neoplasms meeting any of the following criteria:
Mycosis fungoides or Sezary syndrome
Anaplastic large cell lymphoma, peripheral T-cell lymphoma unspecified, or angioimmunoblastic T-cell lymphoma meeting the following criteria:
Hepatosplenic T-cell lymphoma or adult T-cell leukemia/lymphoma
Hodgkin's lymphoma
Acute lymphocytic leukemia meeting any of the following criteria:
Acute myelogenous leukemia or myelodysplasia meeting any of the following criteria:
Chronic myelogenous leukemia meeting any of the following criteria:
Solid tumor, including any of the following:
Renal cell carcinoma
Bladder cancer or gastric cancer
Prostate cancer
Testicular cancer
Pancreatic cancer
Hepatocellular carcinoma
Colorectal carcinoma
Breast cancer meeting any of the following criteria:
Lung cancer (non-small cell or small cell lung cancer), ovarian cancer, endometrial cancer, or cervical cancer
Malignant melanoma
Sarcoma meeting any of the following criteria:
Measurable disease
Must have received prior available standard therapy for specific disease OR not a candidate for this treatment
No CNS malignancy
HLA-partially matched (≥ 2/6 HLA antigen [A, B, DR]) related donor (above 18 years of age) available
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Primary purpose
Allocation
Interventional model
Masking
37 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal